170 related articles for article (PubMed ID: 23353165)
1. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
Wang H; Wang M; Lian G; Wu D
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jan; 33(1):99-102. PubMed ID: 23353165
[TBL] [Abstract][Full Text] [Related]
2. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
Wang HR; Wang MH; Lian GY; Wu DG
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jan; 35(1):99-102. PubMed ID: 25613619
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
Ha SY; Kim SH
Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
[TBL] [Abstract][Full Text] [Related]
4. Analyzing simultaneous positive expression of EZH2 and P53 protein to improve predictive value in cervical squamous cell carcinoma.
Chen SQ; Zhang HM; Li JB; Jiang HY; Fan L; Kong LZ; Yao SZ
Int J Gynecol Cancer; 2014 Nov; 24(9):1653-8. PubMed ID: 25275664
[TBL] [Abstract][Full Text] [Related]
5. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
[TBL] [Abstract][Full Text] [Related]
6. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
He LR; Liu MZ; Li BK; Jia WH; Zhang Y; Liao YJ; Chen YC; Zhang LJ; Guan XY; Zeng YX; Kung HF; Xie D
Int J Cancer; 2010 Jul; 127(1):138-47. PubMed ID: 19904743
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma.
Huang SD; Yuan Y; Zhuang CW; Li BL; Gong DJ; Wang SG; Zeng ZY; Cheng HZ
Mol Cancer; 2012 Aug; 11():51. PubMed ID: 22867052
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of expression of enhancer of zeste homolog 2 and 53 in cervical squamous cell carcinoma and intraepithelial neoplasia].
Zhang H; Chen S; Niu G; Jiang H; Yao S
Zhonghua Zhong Liu Za Zhi; 2014 Aug; 36(8):597-601. PubMed ID: 25430026
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA MALAT1 promotes malignant development of esophageal squamous cell carcinoma by targeting β-catenin via Ezh2.
Wang W; Zhu Y; Li S; Chen X; Jiang G; Shen Z; Qiao Y; Wang L; Zheng P; Zhang Y
Oncotarget; 2016 May; 7(18):25668-82. PubMed ID: 27015363
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of lncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2.
Wu Y; Hu L; Liang Y; Li J; Wang K; Chen X; Meng H; Guan X; Yang K; Bai Y
Mol Cancer; 2017 Aug; 16(1):150. PubMed ID: 28854977
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
13. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
[TBL] [Abstract][Full Text] [Related]
15. miR-101 suppresses tumor proliferation and migration, and induces apoptosis by targeting EZH2 in esophageal cancer cells.
Lin C; Huang F; Li QZ; Zhang YJ
Int J Clin Exp Pathol; 2014; 7(10):6543-50. PubMed ID: 25400732
[TBL] [Abstract][Full Text] [Related]
16. EZH2 overexpression in head and neck cancer is related to lymph node metastasis.
Nienstedt JC; Schroeder C; Clauditz T; Simon R; Sauter G; Muenscher A; Blessmann M; Hanken H; Pflug C
J Oral Pathol Med; 2018 Mar; 47(3):240-245. PubMed ID: 29285811
[TBL] [Abstract][Full Text] [Related]
17. Role of EZH2 in oral squamous cell carcinoma carcinogenesis.
Zhao L; Yu Y; Wu J; Bai J; Zhao Y; Li C; Sun W; Wang X
Gene; 2014 Mar; 537(2):197-202. PubMed ID: 24424512
[TBL] [Abstract][Full Text] [Related]
18. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Koumangoye RB; Andl T; Taubenslag KJ; Zilberman ST; Taylor CJ; Loomans HA; Andl CD
Mol Cancer; 2015 Feb; 14():24. PubMed ID: 25644061
[TBL] [Abstract][Full Text] [Related]
19. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of high-mobility group A2: A novel independent indicator of poor prognosis in patients with esophageal squamous cell carcinoma.
Wei R; Shang Z; Leng J; Cui L
J Cancer Res Ther; 2016; 12(4):1291-1297. PubMed ID: 28169242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]